Bayer

Bayer launches precision health unit in latest digital health venture
Bayer launches precision health unit in latest digital health venture
BioPharma Dive
Bayer
consumer health
digital health
precision health
Flag link:
Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
BioSpace
Bayer
Cedilla Therapeutics
CyclinE1/CDK2 inhibitors
oncology
precision oncology
Flag link:
Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
Bayer's acting BD chief lobbies for the job the only way he knows how: by making deals
Bayer's acting BD chief lobbies for the job the only way he knows how: by making deals
Fierce Biotech
Bayer
business development
Flag link:
Bayer, Amgen looked at Iveric before agreeing to Astellas sale
Bayer, Amgen looked at Iveric before agreeing to Astellas sale
Seeking Alpha
Astellas
Iveric Bio
Bayer
Amgen
M&A
Flag link:
The waxing and waning of the speedy approval
The waxing and waning of the speedy approval
EP Vantage
FDA
drug approvals
accelerated approvals
AbbVie
AstraZeneca
Bayer
Bristol Myers Squibb
JNJ
Merck
Merck KGaA
Novartis
Pfizer
Flag link:
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
BioSpace
Bayer
Bicycle Therapeutics
drug development
radiopharmaceuticals
Flag link:
Drugmakers take sides in Amgen, Regeneron fight over antibody patents
Drugmakers take sides in Amgen, Regeneron fight over antibody patents
BioPharma Dive
Amgen
Regeneron Pharmaceuticals
Sanofi
Supreme Court
patents
Pfizer
Bayer
Roche
Genentech
AstraZeneca
JNJ
Flag link:
Finding the big spenders beyond big pharma
Finding the big spenders beyond big pharma
EP Vantage
R&D
Amgen
Bayer
Biogen
Gilead Sciences
Merck KGaA
Moderna Therapeutics
Novo Nordisk
Regeneron Pharmaceuticals
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Bayer's incoming CEO Anderson won't rule out consumer, agriculture spinoffs: report
Bayer's incoming CEO Anderson won't rule out consumer, agriculture spinoffs: report
Fierce Pharma
Bayer
Bill Anderson
Pharma CEOs
spinoffs
consumer health
Flag link:
Bayer study finds communication gap in managing chronic kidney disease in patients with type 2 diabetes
Bayer study finds communication gap in managing chronic kidney disease in patients with type 2 diabetes
Medical Marketing and Media
Bayer
diabetes
chronic kidney disease
healthcare providers
physicians
Flag link:
Bayer Plans to Double Down on US Pharma R&D in 2023
Bayer Plans to Double Down on US Pharma R&D in 2023
BioSpace
Bayer
R&D
Flag link:
Bayer grapples with Eylea sales slowdown, sees trend continuing in 2023
Bayer grapples with Eylea sales slowdown, sees trend continuing in 2023
Fierce Pharma
Bayer
earnings
Eylea
Flag link:
Bayer's 3 business units 'perfectly positioned,' trade union says in resistance to potential breakup
Bayer's 3 business units 'perfectly positioned,' trade union says in resistance to potential breakup
Fierce Pharma
Bayer
Roche
Werner Baumann
restructuring
Flag link:
Bayer begins key tests for closely watched blood thinner
Bayer begins key tests for closely watched blood thinner
BioPharma Dive
Bayer
clinical trials
bloodthinners
asundexian
Flag link:
Bayer taps Roche's Bill Anderson to lead pharma giant as CEO
Bayer taps Roche's Bill Anderson to lead pharma giant as CEO
Endpoints
Bayer
Bill Anderson
Roche
Pharma CEOs
Flag link:
Pharma responds to Turkey/Syria earthquake
Pharma responds to Turkey/Syria earthquake
Pharmaphorum
philanthropy
earthquake
Turkey
Syria
Bayer
Procter & Gamble
Flag link:
Bayer under investor pressure to speed up CEO changeover
Bayer under investor pressure to speed up CEO changeover
Reuters
Bayer
investors
Pharma CEOs
Werner Baumann
Flag link:
Bayer’s oncology business looks to collect $10B in sales by 2030, exec says
Bayer’s oncology business looks to collect $10B in sales by 2030, exec says
Fierce Pharma
Bayer
oncology
prostatce caner
Nubeqa
Christine Roth
Flag link:

Pages